These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27755932)

  • 41. Region of Interest Selection in Nonclinical Studies of Accumulated Gadolinium-based Contrast Agent-induced T1 Hyperintensity in Deep Cerebellar Nuclei.
    Idée JM; Robert P; Raynaud JS; Rasschaert M; Fretellier N; Factor C; Corot C
    Radiology; 2018 Apr; 287(1):360-362. PubMed ID: 29558301
    [No Abstract]   [Full Text] [Related]  

  • 42. Distribution and chemical forms of gadolinium in the brain: a review.
    Kanda T; Nakai Y; Hagiwara A; Oba H; Toyoda K; Furui S
    Br J Radiol; 2017 Nov; 90(1079):20170115. PubMed ID: 28749164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional imaging of the heart. Role of magnetic resonance imaging contrast media.
    Higgins CB
    Invest Radiol; 1993 Sep; 28 Suppl 4():S38-42. PubMed ID: 8225901
    [No Abstract]   [Full Text] [Related]  

  • 44. Notes on "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent".
    Runge VM
    AJR Am J Roentgenol; 2008 Jun; 190(6):1433-4. PubMed ID: 18492887
    [No Abstract]   [Full Text] [Related]  

  • 45. More on pseudohypocalcemia and gadolinium-enhanced MRI.
    Prince MR; Choyke PL; Knopp MV
    N Engl J Med; 2004 Jan; 350(1):87-8; author reply 87-8. PubMed ID: 14702437
    [No Abstract]   [Full Text] [Related]  

  • 46. Cutaneous nodules, pain, and thrombophlebitis as an adverse reaction to gadolinium contrast media.
    Murphy KJ; Hansen R; Prince MR
    AJR Am J Roentgenol; 1997 Jul; 169(1):318-9. PubMed ID: 9207574
    [No Abstract]   [Full Text] [Related]  

  • 47. Molecularly Targeted MR Imaging Agent in Liver Fibrosis: High Sensitivity and Low Gadolinium Mean High Translational Potential.
    Pomper MG; Lee S
    Radiology; 2018 May; 287(2):590-591. PubMed ID: 29668411
    [No Abstract]   [Full Text] [Related]  

  • 48. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent.
    Sirlin CB; Vera DR; Corbeil JA; Caballero MB; Buxton RB; Mattrey RF
    Acad Radiol; 2004 Dec; 11(12):1361-9. PubMed ID: 15596374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Indications for gadolinium-DTPA in magnetic resonance evaluation of extracranial head and neck mass lesions: review of experience with 27 patients examined with a 2 tesla imager.
    Chisin R; Gomori JM; Elidan J
    Isr J Med Sci; 1992; 28(3-4):268-76. PubMed ID: 1592599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents.
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2008 Aug; 59(2):356-8. PubMed ID: 18638638
    [No Abstract]   [Full Text] [Related]  

  • 51. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
    Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
    Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disappearance of T1-weighted MRI Hyperintensity in Dentate Nuclei of Individuals with a History of Repeat Gadolinium Administration.
    Adin ME; Yousem DM
    Radiology; 2018 Sep; 288(3):911-912. PubMed ID: 30063190
    [No Abstract]   [Full Text] [Related]  

  • 53. Reversible late gadolinium enhancement in a case of Takotsubo cardiomyopathy following high-dose dobutamine stress MRI.
    Bruder O; Hunold P; Jochims M; Waltering KU; Sabin GV; Barkhausen J
    Int J Cardiol; 2008 Jun; 127(1):e22-4. PubMed ID: 17467826
    [No Abstract]   [Full Text] [Related]  

  • 54. [Oral contrast medium for magnetic resonance tomography of the abdomen. II. Phase I clinical testing of gadolinium-DTPA].
    Kornmesser W; Laniado M; Hamm B; Clauss W; Weinmann HJ; Schulz E; Wolf KJ; Felix R
    Rofo; 1987 Nov; 147(5):550-6. PubMed ID: 2825293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gd-DTPA-enhanced MR imaging in mediastinal Hodgkin's disease.
    Forsgren G; Nyman R; Glimelius B; Hagberg H; Rehn S; Hemmingsson A
    Acta Radiol; 1994 Nov; 35(6):564-9. PubMed ID: 7946679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Initial experience with the use of oral gadolinium-DTPA in nuclear magnetic resonance tomography of the pelvis].
    Hötzinger H; Salbeck R; Toedt C; Beyer HK
    Digitale Bilddiagn; 1990 Jun; 10(2):42-5. PubMed ID: 2208914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The use of gadolinium-DTPA in inflammatory bone diseases].
    Müller-Miny H; Reiser M; Erlemann R; Peters PE
    Radiol Diagn (Berl); 1989; 30(4):491-5. PubMed ID: 2798837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [MRT of experimental liver abscesses: a comparison of a new blood pool contrast medium with gadolinium-DTPA in animal experiments].
    Dick A; Adam G; Spüntrup E; Prescher A; Mühler A; Günther RW
    Rofo; 1996 Oct; 165(4):392-7. PubMed ID: 8963054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
    Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
    Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gadolinium Deposition in the Pediatric Brain.
    Roberts DR; Welsh CA; Davis WC
    JAMA Pediatr; 2017 Dec; 171(12):1229. PubMed ID: 29052686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.